多発性骨髄腫CAR T細胞療法の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)

【英語タイトル】Global CAR T-Cell Therapy for Multiple Myeloma Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

GlobalInfoResearchが出版した調査資料(GIR8100949)・商品コード:GIR8100949
・発行会社(調査会社):GlobalInfoResearch
・発行日:2018年10月15日(※2024年版があります。お問い合わせください)
・ページ数:117
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:世界
・産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは、多発性骨髄腫CAR T細胞療法の世界市場について調べ、まとめました。種類別セグメントは、単剤療法、コンビネーションセラピー等、用途別セグメントは、多発性骨髄腫、難治性または再発多発性骨髄腫等に区分しました。多発性骨髄腫CAR T細胞療法の世界市場概観、メーカー動向、メーカー別多発性骨髄腫CAR T細胞療法シェア、市場規模推移、市場規模予測、主要地域分析(北米、ヨーロッパ、アジア等)、主要国分析(日本、中国、アメリカ等)データなどの情報が含まれています。
・多発性骨髄腫CAR T細胞療法の市場概観
・多発性骨髄腫CAR T細胞療法のメーカー概要(事業概要、製品種類、価格、売上、市場シェア等)
・多発性骨髄腫CAR T細胞療法のメーカー別販売動向、市場シェア、市場集中度、競争動向
・多発性骨髄腫CAR T細胞療法の世界市場規模
・多発性骨髄腫CAR T細胞療法の北米市場分析(アメリカ、カナダ、メキシコ等)
・多発性骨髄腫CAR T細胞療法のアメリカ市場規模推移
・多発性骨髄腫CAR T細胞療法のカナダ市場規模推移
・多発性骨髄腫CAR T細胞療法のメキシコ市場規模推移
・多発性骨髄腫CAR T細胞療法のヨーロッパ市場分析(ドイツ、イギリス、ロシア、フランス、イタリア等)
・多発性骨髄腫CAR T細胞療法のドイツ市場規模推移
・多発性骨髄腫CAR T細胞療法のイギリス市場規模推移
・多発性骨髄腫CAR T細胞療法のロシア市場規模推移
・多発性骨髄腫CAR T細胞療法のアジア市場分析(日本、中国、韓国、インド、東南アジア等)
・多発性骨髄腫CAR T細胞療法の日本市場規模推移
・多発性骨髄腫CAR T細胞療法の中国市場規模推移
・多発性骨髄腫CAR T細胞療法の韓国市場規模推移
・多発性骨髄腫CAR T細胞療法のインド市場規模推移
・多発性骨髄腫CAR T細胞療法の東南アジア市場規模推移
・多発性骨髄腫CAR T細胞療法の南米市場分析(ブラジル、アルゼンチン等)
・多発性骨髄腫CAR T細胞療法の中東・アフリカ市場分析(サウジアラビア、UAE、南アフリカ等)
・多発性骨髄腫CAR T細胞療法の種類別分析/市場規模推移(単剤療法、コンビネーションセラピー)
・多発性骨髄腫CAR T細胞療法の用途別分析/市場規模推移(多発性骨髄腫、難治性または再発多発性骨髄腫)
・多発性骨髄腫CAR T細胞療法の市場予測(地域別予測、種類別予測、用途別予測)
・多発性骨髄腫CAR T細胞療法の販売チャネル・代理店・貿易業者・ディーラー分析
【レポートの概要】

CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual’s own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma. 

Scope of the Report:

This report studies the CAR T-Cell Therapy for Multiple Myeloma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the CAR T-Cell Therapy for Multiple Myeloma market by product type and applications/end industries.

The increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area. Car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.

The global CAR T-Cell Therapy for Multiple Myeloma market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of CAR T-Cell Therapy for Multiple Myeloma.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Juno Therapeutics

Kite Pharma

Novartis

Collectis

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Monotherapy

Combination Therapy

Market Segment by Applications, can be divided into

Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

【レポートの目次】

Table of Contents

1 CAR T-Cell Therapy for Multiple Myeloma Market Overview

1.1 Product Overview and Scope of CAR T-Cell Therapy for Multiple Myeloma

1.2 Classification of CAR T-Cell Therapy for Multiple Myeloma by Types

1.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Comparison by Types (2017-2023)

1.2.2 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Types in 2017

1.2.3 Monotherapy

1.2.4 Combination Therapy

1.3 Global CAR T-Cell Therapy for Multiple Myeloma Market by Application

1.3.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Multiple Myeloma

1.3.3 Refractory or Relapsed Multiple Myeloma

1.4 Global CAR T-Cell Therapy for Multiple Myeloma Market by Regions

1.4.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)

1.5 Global Market Size of CAR T-Cell Therapy for Multiple Myeloma (2013-2023)

2 Manufacturers Profiles

2.1 Juno Therapeutics

2.1.1 Business Overview

2.1.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

2.2 Kite Pharma

2.2.1 Business Overview

2.2.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

2.3 Novartis

2.3.1 Business Overview

2.3.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

2.4 Collectis

2.4.1 Business Overview

2.4.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

3 Global CAR T-Cell Therapy for Multiple Myeloma Market Competition, by Players

3.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 CAR T-Cell Therapy for Multiple Myeloma Players Market Share

3.2.2 Top 10 CAR T-Cell Therapy for Multiple Myeloma Players Market Share

3.3 Market Competition Trend

4 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Regions

4.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue and Market Share by Regions

4.2 North America CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

4.3 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

4.5 South America CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

5 North America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries

5.1 North America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)

5.2 USA CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

5.3 Canada CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

5.4 Mexico CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

6 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries

6.1 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)

6.2 Germany CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

6.3 UK CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

6.4 France CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

6.5 Russia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

6.6 Italy CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

7 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries

7.1 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)

7.2 China CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

7.3 Japan CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

7.4 Korea CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

7.5 India CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

8 South America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries

8.1 South America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)

8.2 Brazil CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

8.3 Argentina CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

8.4 Colombia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue CAR T-Cell Therapy for Multiple Myeloma by Countries

9.1 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)

9.2 Saudi Arabia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

9.3 UAE CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

9.4 Egypt CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

9.5 Nigeria CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

9.6 South Africa CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

10 Global CAR T-Cell Therapy for Multiple Myeloma Market Segment by Type

10.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue and Market Share by Type (2013-2018)

10.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Forecast by Type (2018-2023)

10.3 Monotherapy Revenue Growth Rate (2013-2023)

10.4 Combination Therapy Revenue Growth Rate (2013-2023)

11 Global CAR T-Cell Therapy for Multiple Myeloma Market Segment by Application

11.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Application (2013-2018)

11.2 CAR T-Cell Therapy for Multiple Myeloma Market Forecast by Application (2018-2023)

11.3 Multiple Myeloma Revenue Growth (2013-2018)

11.4 Refractory or Relapsed Multiple Myeloma Revenue Growth (2013-2018)

12 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Forecast (2018-2023)

12.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Forecast (2018-2023)

12.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Forecast by Regions (2018-2023)

12.3 North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

12.4 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

12.6 South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures



Figure CAR T-Cell Therapy for Multiple Myeloma Picture

Table Product Specifications of CAR T-Cell Therapy for Multiple Myeloma

Table Global CAR T-Cell Therapy for Multiple Myeloma and Revenue (Million USD) Market Split by Product Type

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Types in 2017

Figure Monotherapy Picture

Figure Combination Therapy Picture

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) by Application (2013-2023)

Figure CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Applications in 2017

Figure Multiple Myeloma Picture

Figure Refractory or Relapsed Multiple Myeloma Picture

Table Global Market CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) Comparison by Regions 2013-2023

Figure North America CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate (2013-2023)

Figure Europe CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate (2013-2023)

Figure Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate (2013-2023)

Figure South America CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate (2013-2023)

Figure Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate (2013-2023)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate (2013-2023)

Table Juno Therapeutics Basic Information, Manufacturing Base and Competitors

Table Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Type and Applications

Table Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

Table Kite Pharma Basic Information, Manufacturing Base and Competitors

Table Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Type and Applications

Table Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

Table Novartis Basic Information, Manufacturing Base and Competitors

Table Novartis CAR T-Cell Therapy for Multiple Myeloma Type and Applications

Table Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

Table Collectis Basic Information, Manufacturing Base and Competitors

Table Collectis CAR T-Cell Therapy for Multiple Myeloma Type and Applications

Table Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) by Players (2013-2018)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Players (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Players in 2016

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Players in 2017

Figure Global Top 5 Players CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share in 2017

Figure Global Top 10 Players CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share in 2017

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate (%) (2013-2018)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) by Regions (2013-2018)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Regions (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Regions (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Regions in 2017

Figure North America CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Europe CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure South America CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Table North America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)

Table North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries in 2017

Figure USA CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Canada CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Mexico CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Table Europe CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) by Countries (2013-2018)

Figure Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries in 2017

Figure Germany CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure UK CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure France CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Russia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Italy CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Table Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) by Countries (2013-2018)

Figure Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries in 2017

Figure China CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Japan CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Korea CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure India CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Table South America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)

Table South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries in 2017

Figure Brazil CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Argentina CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Colombia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Table Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) by Countries (2013-2018)

Table Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Countries in 2017

Figure Saudi Arabia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure UAE CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Egypt CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure Nigeria CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Figure South Africa CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) by Type (2013-2018)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Type (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Type (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Type in 2017

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue Forecast by Type (2018-2023)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Market Share Forecast by Type (2018-2023)

Figure Global Monotherapy Revenue Growth Rate (2013-2018)

Figure Global Combination Therapy Revenue Growth Rate (2013-2018)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue by Application (2013-2018)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Application (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Application (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Application in 2017

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue Forecast by Application (2018-2023)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Market Share Forecast by Application (2018-2023)

Figure Global Multiple Myeloma Revenue Growth Rate (2013-2018)

Figure Global Refractory or Relapsed Multiple Myeloma Revenue Growth Rate (2013-2018)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) and Growth Rate Forecast (2018 -2023)

Table Global CAR T-Cell Therapy for Multiple Myeloma Revenue (Million USD) Forecast by Regions (2018-2023)

Figure Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share Forecast by Regions (2018-2023)

Figure North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

Figure Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

Figure Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

Figure South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)

Figure Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)



【レポートのキーワード】

多発性骨髄腫CAR T細胞療法、単剤療法、コンビネーションセラピー、多発性骨髄腫、難治性または再発多発性骨髄腫

★調査レポート[多発性骨髄腫CAR T細胞療法の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)] (コード:GIR8100949)販売に関する免責事項を必ずご確認ください。
★調査レポート[多発性骨髄腫CAR T細胞療法の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆